$1.45
0.075.07%
At close: -
$1.46
0.008600.59%
After Hours: May 2, 4:36 PM EDT
Comments
Loading...
Ventyx Biosciences Analyst Ratings and Price Targets | NASDAQ:VTYX | Benzinga
Ventyx Biosciences Inc has a consensus price target of $22.78 based on the ratings of 10 analysts. The high is $62 issued by Credit Suisse on August 11, 2023. The low is $2 issued by Stifel on December 18, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Oppenheimer, and HC Wainwright & Co. on November 11, 2024, November 8, 2024, and October 15, 2024, respectively. With an average price target of $7 between HC Wainwright & Co., Oppenheimer, and HC Wainwright & Co., there's an implied 379.91% upside for Ventyx Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
Wells Fargo
Canaccord Genuity
Stifel
Evercore ISI Group
1calculated from analyst ratings
Analyst Ratings for Ventyx Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 01/14/2025 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | — | Reiterates | Neutral → Neutral | Get Alert |
| 11/11/2024 | Buy Now | 311.35% | HC Wainwright & Co. | Emily Bodnar38% | $6 → $6 | Reiterates | Neutral → Neutral | Get Alert |
| 11/08/2024 | Buy Now | 517.03% | Oppenheimer | Jeff Jones33% | $10 → $9 | Reiterates | Outperform → Outperform | Get Alert |
| 10/15/2024 | Buy Now | 311.35% | HC Wainwright & Co. | Emily Bodnar38% | $6 → $6 | Reiterates | Neutral → Neutral | Get Alert |
| 09/23/2024 | Buy Now | 311.35% | HC Wainwright & Co. | Emily Bodnar38% | $6 → $6 | Reiterates | Neutral → Neutral | Get Alert |
| 08/12/2024 | Buy Now | 654.15% | Wells Fargo | Derek Archila60% | $16 → $11 | Maintains | Overweight | Get Alert |
| 08/12/2024 | Buy Now | 859.82% | Canaccord Genuity | Edward Nash68% | $15 → $14 | Maintains | Buy | Get Alert |
| 07/30/2024 | Buy Now | 311.35% | HC Wainwright & Co. | Emily Bodnar38% | $6 → $6 | Reiterates | Neutral → Neutral | Get Alert |
| 06/13/2024 | Buy Now | 311.35% | HC Wainwright & Co. | Emily Bodnar38% | $6 → $6 | Reiterates | Neutral → Neutral | Get Alert |
| 06/06/2024 | Buy Now | 585.59% | Oppenheimer | Jeff Jones33% | $12 → $10 | Maintains | Outperform | Get Alert |
| 06/06/2024 | Buy Now | 311.35% | HC Wainwright & Co. | Emily Bodnar38% | $6 → $6 | Reiterates | Neutral → Neutral | Get Alert |
| 03/13/2024 | Buy Now | 928.38% | Canaccord Genuity | Edward Nash68% | $16 → $15 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | 722.71% | Oppenheimer | Jeff Jones33% | → $12 | Upgrade | Perform → Outperform | Get Alert |
| 03/12/2024 | Buy Now | 996.94% | Wells Fargo | Derek Archila60% | $7 → $16 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 03/11/2024 | Buy Now | 996.94% | Canaccord Genuity | Edward Nash68% | $20 → $16 | Maintains | Buy | Get Alert |
| 02/21/2024 | Buy Now | — | Oppenheimer | Jeff Jones33% | — | Reiterates | → Perform | Get Alert |
| 12/19/2023 | Buy Now | 105.68% | Wells Fargo | Derek Archila60% | $8 → $3 | Maintains | Equal-Weight | Get Alert |
| 12/18/2023 | Buy Now | 37.12% | Stifel | Alex Thompson43% | $6 → $2 | Maintains | Hold | Get Alert |
| 11/10/2023 | Buy Now | 242.79% | Evercore ISI Group | Josh Schimmer56% | $43 → $5 | Downgrade | Outperform → In-Line | Get Alert |
| 11/07/2023 | Buy Now | 311.35% | Morgan Stanley | Vikram Purohit38% | $46 → $6 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/07/2023 | Buy Now | 311.35% | Stifel | Alex Thompson43% | → $6 | Downgrade | Buy → Hold | Get Alert |
| 11/07/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | — | Downgrade | Buy → Neutral | Get Alert |
| 10/10/2023 | Buy Now | 3739.3% | Stifel | Alex Thompson43% | → $56 | Reiterates | Buy → Buy | Get Alert |
| 10/10/2023 | Buy Now | 3465.06% | HC Wainwright & Co. | Emily Bodnar38% | → $52 | Reiterates | Buy → Buy | Get Alert |
| 08/29/2023 | Buy Now | 3053.71% | Morgan Stanley | Simon Flannery66% | $45 → $46 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | 4150.65% | Credit Suisse | Tiago Fauth43% | $63 → $62 | Maintains | Outperform | Get Alert |
| 08/11/2023 | Buy Now | 3465.06% | HC Wainwright & Co. | Emily Bodnar38% | $54 → $52 | Maintains | Buy | Get Alert |
| 07/05/2023 | Buy Now | 4150.65% | Oppenheimer | Jeff Jones33% | $62 → $62 | Reiterates | Outperform → Outperform | Get Alert |
| 07/05/2023 | Buy Now | 3602.18% | HC Wainwright & Co. | Emily Bodnar38% | $54 → $54 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2023 | Buy Now | 4219.21% | Credit Suisse | Tiago Fauth43% | → $63 | Assumes | → Outperform | Get Alert |
| 05/12/2023 | Buy Now | 3602.18% | HC Wainwright & Co. | Emily Bodnar38% | → $54 | Reiterates | Buy → Buy | Get Alert |
| 03/24/2023 | Buy Now | 4219.21% | Credit Suisse | Tiago Fauth43% | → $63 | Reiterates | → Outperform | Get Alert |
| 03/24/2023 | Buy Now | 4150.65% | Oppenheimer | Jeff Jones33% | $65 → $62 | Maintains | Outperform | Get Alert |
| 03/21/2023 | Buy Now | 5179.03% | Wells Fargo | Derek Archila60% | → $77 | Initiates | → Overweight | Get Alert |
| 03/20/2023 | Buy Now | 3327.94% | HC Wainwright & Co. | Emily Bodnar38% | → $50 | Reiterates | → Buy | Get Alert |
| 01/31/2023 | Buy Now | 3602.18% | Canaccord Genuity | Edward Nash68% | $35 → $54 | Maintains | Buy | Get Alert |
| 01/27/2023 | Buy Now | 4013.53% | Oppenheimer | Jeff Jones33% | $55 → $60 | Maintains | Outperform | Get Alert |
| 12/19/2022 | Buy Now | 3327.94% | Goldman Sachs | Chris Shibutani56% | → $50 | Initiates | → Buy | Get Alert |
| 11/17/2022 | Buy Now | 2985.15% | Morgan Stanley | Simon Flannery66% | → $45 | Initiates | → Overweight | Get Alert |
| 09/16/2022 | Buy Now | 3533.62% | Stifel | Alex Thompson43% | $45 → $53 | Maintains | Buy | Get Alert |
| 09/13/2022 | Buy Now | 3327.94% | HC Wainwright & Co. | Emily Bodnar38% | $36 → $50 | Maintains | Buy | Get Alert |
| 09/12/2022 | Buy Now | 4356.33% | Oppenheimer | Jeff Jones33% | $40 → $65 | Maintains | Outperform | Get Alert |
| 09/07/2022 | Buy Now | 2985.15% | Stifel | Alex Thompson43% | → $45 | Initiates | → Buy | Get Alert |
| 09/01/2022 | Buy Now | 2368.12% | HC Wainwright & Co. | Emily Bodnar38% | → $36 | Initiates | → Buy | Get Alert |
| 08/17/2022 | Buy Now | 2299.56% | Canaccord Genuity | Edward Nash68% | $30 → $35 | Maintains | Buy | Get Alert |
| 08/16/2022 | Buy Now | 4219.21% | Credit Suisse | Tiago Fauth43% | $53 → $63 | Maintains | Outperform | Get Alert |
| 08/16/2022 | Buy Now | 2642.36% | Oppenheimer | Jeff Jones33% | $30 → $40 | Maintains | Outperform | Get Alert |
| 05/09/2022 | Buy Now | 3533.62% | Credit Suisse | Tiago Fauth43% | → $53 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Ventyx Biosciences (VTYX) stock?
The latest price target for Ventyx Biosciences (NASDAQ:VTYX) was reported by HC Wainwright & Co. on January 14, 2025. The analyst firm set a price target for $0.00 expecting VTYX to fall to within 12 months (a possible -100.00% downside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ventyx Biosciences (VTYX)?
The latest analyst rating for Ventyx Biosciences (NASDAQ:VTYX) was provided by HC Wainwright & Co., and Ventyx Biosciences reiterated their neutral rating.
When was the last upgrade for Ventyx Biosciences (VTYX)?
The last upgrade for Ventyx Biosciences Inc happened on March 12, 2024 when Oppenheimer raised their price target to $12. Oppenheimer previously had a perform for Ventyx Biosciences Inc.
When was the last downgrade for Ventyx Biosciences (VTYX)?
The last downgrade for Ventyx Biosciences Inc happened on November 10, 2023 when Evercore ISI Group changed their price target from $43 to $5 for Ventyx Biosciences Inc.
When is the next analyst rating going to be posted or updated for Ventyx Biosciences (VTYX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ventyx Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ventyx Biosciences was filed on January 14, 2025 so you should expect the next rating to be made available sometime around January 14, 2026.
Is the Analyst Rating Ventyx Biosciences (VTYX) correct?
While ratings are subjective and will change, the latest Ventyx Biosciences (VTYX) rating was a reiterated with a price target of $0.00 to $0.00. The current price Ventyx Biosciences (VTYX) is trading at is $1.46, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
